Quality by Design in Excipients - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Quality by Design in Excipients
Factors for assessing excipient variability, the associated challenges developers need to address to design and manufacture solid oral drug products, and solutions for such challenges are examined.


Pharmaceutical Technology
pp. s26-s28

Along with the specified parameters, it is important to also consider both unspecified parameters as well as nonroutine parameters. The variability of unspecified or unreported parameters, could impact drug-product performance depending upon its design and intended use. Although unreported, these properties may be measured by the manufacturer as part of its control strategy. In addition, excipients can vary in what is termed nonroutine parameters (e.g., residual reactants and residual catalysts). Variation of these parameters may not be commonly measured by the manufacturer.

So in the majority of cases, robust drug products are successfully developed and manufactured to manage such excipient variability. Failure, however, to understand and control excipient variability has indeed led to some serious quality issues.

FDA, for example, has spoken publicly about excipient variability and its relation to drug-product recalls from the market. It is clear that some existing development and manufacturing practices can fail to ensure that medicines of the appropriate quality standards that are routinely produced. Furthermore, demonstrating quality by testing does not prevent these substandard drug products from entering the market. Obviously, quality failures, including those related to excipient variability, can have serious consequences to the manufacturer in terms of financial and reputational damage. Ultimately, the end user, the patient, is put at risk.

Substandard drug products reaching the patient can impact safety and efficacy. And even those that are captured and rejected by quality control or those recalled from the market can lead to drug shortages. This, again, impacts the patient. So, with increasing public focus upon the pharmaceutical industry and regulators alike, it is clear that managing excipient variability will be an area of increasing industry importance.

It is critical, therefore, for excipient manufacturers and vendors to closely collaborate with the developer to better reduce the risks of quality failures. This is important from early on in the drug product's development, whereby knowledge and experience of the excipient can proactively support robust formulation design and efficient manufacturing control. Failure to account for normal excipient variability can lead to the design and development of nonrobust formulations. Unfortunately, this can necessitate tighter excipient-specification test limits, batch selection, or even custom manufacture to control the performance of the finished drug product.

It must be recognized that, in some instances, the ability of the excipient manufacturer to meet such requirements may not be easily achieved, if achievable at all. This, therefore, presents additional risk and cost to the overall product.

It also is important to consider the interplay of all variables including those of the API and the manufacturing process. The use of risk assessment is helpful to identify those primary variables that may affect the drug product's critical quality attributes.

So, the ability of the developer to determine the effects and interactions of excipient material attributes, along with API and processing parameters, using approaches such as design of experiments, can provide valuable insight into their true criticality upon drug-product quality.

Using QbD, therefore, presents an opportunity to ensure quality is built in by design. Early collaboration by all stakeholders can better ensure that the potential risks of normal excipient variability can be efficiently designed out by our prior knowledge and available tools.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
26%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
43%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here